CClinicalTrials.gg
Sign In
WithdrawnNCT02952196Updated Oct 23, 2020

Cannabioids as a New Intervention for Amphetamine Dependence

A Phase 2 interventional study of drug administration in Amphetamine Addiction, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Withdrawn at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-23.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 2, Interventional, and Prevention

Why this study was withdrawn
Funding
Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder.

The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

02

Conditions studied

  • Amphetamine Addiction

Keywords

  • Amphetamine
  • Cannabinoids
03

In context

Amphetamine-Related Disorders

58 studies on the registry are indexed under Amphetamine-Related Disorders; 4 are open to participants now.

Browse Amphetamine-Related Disorders studies →

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 370 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Current DSM-V criteria for amphetamine use disorder
  • Ability to give valid, informed consent

Exclusion criteria

Exclusion Criteria:

  • Severe and/or unstable hepatic, neurologic (including diagnosis of seizures), cardiac (including arrhythmias) or renal disease, or any other severe or unstable medical condition that precludes safe participation in the study according to the study physician.
  • Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or severe suicidality
  • Any serious medical condition or psychiatric illness that precludes the subject from signing the informed consent form
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: drug administration

  • Experimental
    cannabinoid dose 1

    Drug: drug administration

  • Experimental
    cannabinoid dose 2

    Drug: drug administration

Interventions

  • Drugdrug administration

    administering drug to patient with amphetamine addiction

06

What researchers measure

Primary outcomes

  1. assessing amphetamine craving

    using questionnaire to assess craving and taking vital signs

    Time frame: everyday during the study (that will last 3 days for each participants)

07

Study locations

1 site
  • Centre hospitalier de l'Université de Montréal
    Montreal, Quebec, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02952196
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Responsible party
Sponsor
First posted
Nov 2, 2016
Start date
Nov 2016 (estimated)
Primary completion
Dec 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Oct 23, 2020

Study contacts

Didier Jutras-Aswad, MD, MS
principal investigator · Centre hospitalier de l'Université de Montréal (CHUM)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Amphetamine-Related Disorders→

Other studies from this sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Start the discussion